Compare BAND & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAND | ANGO |
|---|---|---|
| Founded | 2000 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.6M | 400.8M |
| IPO Year | 2017 | 2004 |
| Metric | BAND | ANGO |
|---|---|---|
| Price | $15.26 | $13.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $20.80 | $19.33 |
| AVG Volume (30 Days) | 209.5K | ★ 465.8K |
| Earning Date | 10-30-2025 | 01-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $756,118,000.00 | $300,718,000.00 |
| Revenue This Year | $2.82 | $8.18 |
| Revenue Next Year | $15.10 | $5.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.42 | 2.73 |
| 52 Week Low | $11.33 | $8.27 |
| 52 Week High | $20.23 | $13.99 |
| Indicator | BAND | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 56.85 | 58.82 |
| Support Level | $13.75 | $13.12 |
| Resistance Level | $15.74 | $13.53 |
| Average True Range (ATR) | 0.51 | 0.43 |
| MACD | 0.18 | 0.02 |
| Stochastic Oscillator | 80.10 | 61.80 |
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of the company's revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.